Vicebio, a London, UK-based biopharmaceutical company developing novel vaccines against life-threatening respiratory viral infections, raised $100M in Series B funding.
The round was led by TCGX with investment from Goldman Sachs Alternatives, Avoro Ventures, venBio, and participation from UniQuest, and founding investor Medicxi.
The company intends to use the funds to accelerate development of multivalent respiratory virus vaccines using proprietary molecular clamp technology.
Led by CEO Dr Emmanuel Hanon, Vicebio is developing vaccines for respiratory viruses utilising its proprietary molecular clamp technology, discovered at The University of Queensland, which stabilises viral glycoproteins in their highly immunogenic ‘prefusion’ conformation. This technology is applicable to a wide range of viruses including respiratory syncytial virus (RSV), human metapneumovirus, parainfluenza virus, influenza and coronaviruses, as confirmed by preclinical and clinical studies.
The company has recently initiated a Phase I clinical trial with VXB-241, its bivalent vaccine targeting both RSV and hMPV viruses that cause a significant burden of disease in elderly patients and those with a weakened immune system.
Initial clinical readouts of the Phase 1 study are expected mid 2025.
FinSMEs
23/09/2024